Vice President & Head, U.S. Vaccines R&D Center: Ripley Ballou
About GSK: The soon-to-open GSK Global Vaccines US R&D Center is a critical component of GSK and its vision of being the leader in the field of vaccines. The state-of-the-art facility will be at the forefront of vaccine research and development, combatting some of the most important diseases known to man and addressing the medical needs of people of all ages around the world. It is home to some of the best scientific minds in vaccine research and development, who will work collaboratively with the Vaccines R&D centers in Italy and Belgium.
Why Rockville: Located in the research-rich Washington, D.C., area, the center establishes a vital footprint for GSK Vaccines in the U.S. market and serves as a center of research and development excellence in the world’s largest healthcare market. The Center’s proximity to world-renowned academic centers, government-owned laboratories, U.S. government institutions, and external partners will allow the company to reinforce and build new relationships with key scientists and organizations, and access major funding and research resources.